Kakareko Katarzyna, Rydzewska-Rosołowska Alicja, Zbroch Edyta, Hryszko Tomasz
2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland.
Department of Internal Medicine and Hypertension, Medical University of Białystok, 15-276 Białystok, Poland.
J Clin Med. 2021 Mar 18;10(6):1252. doi: 10.3390/jcm10061252.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic protein showing broad biological functions. Data from animal studies indicate that TRAIL may possibly contribute to the pathophysiology of cardiomyopathy, atherosclerosis, ischemic stroke and abdominal aortic aneurysm. It has been also suggested that TRAIL might be useful in cardiovascular risk stratification. This systematic review aimed to evaluate whether TRAIL is a risk factor or risk marker in cardiovascular diseases (CVDs) focusing on major adverse cardiovascular events. Two databases (PubMed and Cochrane Library) were searched until December 2020 without a year limit in accordance to the PRISMA guidelines. A total of 63 eligible original studies were identified and included in our systematic review. Studies suggest an important role of TRAIL in disorders such as heart failure, myocardial infarction, atrial fibrillation, ischemic stroke, peripheral artery disease, and pulmonary and gestational hypertension. Most evidence associates reduced TRAIL levels and increased TRAIL-R2 concentration with all-cause mortality in patients with CVDs. It is, however, unclear whether low TRAIL levels should be considered as a risk factor rather than a risk marker of CVDs. Further studies are needed to better define the association of TRAIL with cardiovascular diseases.
肿瘤坏死因子相关凋亡诱导配体（TRAIL）是一种具有广泛生物学功能的促凋亡蛋白。动物研究数据表明，TRAIL可能与心肌病、动脉粥样硬化、缺血性中风和腹主动脉瘤的病理生理学有关。也有人提出，TRAIL可能有助于心血管疾病风险分层。本系统评价旨在评估TRAIL是否为心血管疾病（CVD）的危险因素或风险标志物，重点关注主要不良心血管事件。根据PRISMA指南，检索了两个数据库（PubMed和Cochrane图书馆），直至2020年12月，无年份限制。共识别出63项符合条件的原始研究并纳入我们的系统评价。研究表明，TRAIL在心力衰竭、心肌梗死、心房颤动、缺血性中风、外周动脉疾病以及肺动脉高压和妊娠期高血压等疾病中发挥重要作用。大多数证据表明，CVD患者中TRAIL水平降低和TRAIL-R2浓度升高与全因死亡率相关。然而，尚不清楚低TRAIL水平应被视为CVD的危险因素还是风险标志物。需要进一步研究以更好地确定TRAIL与心血管疾病的关联。
